Our Chief Business Officer, Elizabeth Hickman, recently authored a guest article in The Medicine Maker. Check it out here:
I’m excited to share my first contributed article for The Medicine Maker published today, which discusses the impact of the Inflation Reduction Act on small molecule-focused CDMOs. “In this era of therapeutics, CDMOs can help redefine the future of small molecule drug development by adopting strategic foresight and adaptability. The challenges we face today present an opportunity for the industry to emerge stronger, more resilient, and even more essential. CDMOs can maintain their crucial role in drug development, address the challenges introduced by the IRA, and help ensure essential medications are available to all who need them by focusing on capabilities that enhance speed, foster innovation, and improve manufacturing efficiency and cost.” Read the full article here: https://lnkd.in/gCiJzPyp #CDMO #SmallMolecule #DrugDevelopment